| Not Yet Recruiting | Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans NCT06766331 | VA Office of Research and Development | N/A |
| Not Yet Recruiting | Genotype and Subtype Mapping of the Hepatitis C Virus NCT07503288 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening NCT06745895 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Unknown | Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis NCT06104046 | Assiut University | — |
| Unknown | Acceptance and Feasibility of Hepatitis c Screening Strategies in Social Insertion Centers NCT05756738 | University of La Laguna | N/A |
| Withdrawn | IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir NCT03639207 | National Cancer Institute (NCI) | — |
| Completed | Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine NCT04038320 | Right to Care | — |
| Completed | Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea NCT02951364 | Gilead Sciences | — |
| Completed | Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infectio NCT02907996 | Gilead Sciences | — |
| Unknown | HCV Care Pathway in Ile-de-France NCT02893046 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Re NCT02692703 | AbbVie | Phase 3 |
| Completed | Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil NCT02773394 | Janssen-Cilag Ltd. | — |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepa NCT02723084 | AbbVie | Phase 3 |
| Completed | An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazili NCT02597270 | Janssen-Cilag Ltd. | — |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Vir NCT02707952 | AbbVie | Phase 3 |
| Completed | The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Ther NCT02581020 | AbbVie | — |
| Completed | A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With H NCT02640157 | AbbVie | Phase 3 |
| Completed | Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C NCT02592057 | Gilead Sciences | — |
| Completed | A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genot NCT02582632 | AbbVie | Phase 3 |
| Completed | The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infect NCT02636595 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection NCT02604017 | AbbVie | Phase 3 |
| Active Not Recruiting | Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatmen NCT02460133 | Nova Scotia Health Authority | Phase 4 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without NCT02442284 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavir NCT02446717 | AbbVie | Phase 2 / Phase 3 |
| Completed | Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir NCT02349048 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin NCT02219477 | AbbVie | Phase 3 |
| Completed | A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administ NCT02265237 | AbbVie | Phase 3 |
| Withdrawn | Japanese Bridging Study Conducted in the United States NCT00947245 | Bristol-Myers Squibb | Phase 1 |
| Completed | Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Ch NCT02207088 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 Wit NCT02243293 | AbbVie | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 Wit NCT02243280 | AbbVie | Phase 2 |
| Completed | Two-way Interaction Between Alisporivir and EDP239 NCT02173574 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Completed | A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic NCT02170727 | Bristol-Myers Squibb | Phase 3 |
| Completed | Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who F NCT02105454 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and W NCT02068222 | AbbVie | Phase 2 |
| Completed | Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and NCT02092350 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Geno NCT02073656 | Gilead Sciences | Phase 3 |
| Completed | A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (H NCT02103699 | Janssen Scientific Affairs, LLC | — |
| Completed | "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard NCT02058173 | Shiraz University of Medical Sciences | Phase 4 |
| Completed | Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults NCT02023112 | AbbVie | Phase 3 |
| Completed | Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Re NCT02002767 | Gilead Sciences | Phase 1 |
| Completed | A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Ge NCT01995071 | AbbVie | Phase 2 |
| Unknown | Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation NCT01836718 | Schiano, Thomas D., MD | — |
| Completed | Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia NCT01741545 | Bristol-Myers Squibb | Phase 3 |
| Withdrawn | Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chr NCT01629732 | Bristol-Myers Squibb | Phase 2 |
| Completed | Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced NCT01838590 | Gilead Sciences | Phase 3 |
| Completed | Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 NCT01713283 | Gilead Sciences | Phase 2 |
| Completed | Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Viru NCT01628692 | Bristol-Myers Squibb | Phase 2 |
| Completed | Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir NCT01598090 | Bristol-Myers Squibb | Phase 3 |
| Completed | Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) NCT01581203 | Bristol-Myers Squibb | Phase 3 |
| Completed | Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) NCT01573351 | Bristol-Myers Squibb | Phase 3 |
| Completed | A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synth NCT01486004 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressan NCT01479881 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxo NCT01396005 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and W NCT01458535 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Sa NCT01381835 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Terminated | TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safet NCT01391117 | Tibotec BVBA | Phase 1 |
| Completed | Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease NCT01605513 | The First Hospital of Jilin University | Phase 1 / Phase 2 |
| Completed | TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC43 NCT01323257 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Give NCT01306617 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Unknown | High Dose Insulin Therapy to Improve Liver Function NCT01271140 | McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A |
| Completed | TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC43 NCT01288742 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection NCT01257204 | Bristol-Myers Squibb | Phase 2 |
| Completed | TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC43 NCT01205139 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC43 NCT01241773 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | Ph IIA Study (SOC +/- NS5B) NCT01193361 | Bristol-Myers Squibb | Phase 2 |
| Completed | Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior NCT01170962 | Bristol-Myers Squibb | Phase 2 |
| Completed | Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected NCT01188772 | Gilead Sciences | Phase 2 |
| Completed | TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivi NCT01124799 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients NCT01125189 | Bristol-Myers Squibb | Phase 2 |
| Completed | TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulat NCT01134718 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | TMC435-TiDP16-C112 - Interaction Trial With Antidepressants NCT01090700 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection NCT01097395 | University of Colorado, Denver | Phase 4 |
| Withdrawn | A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated NCT00814606 | University of Chicago | Phase 2 |
| Completed | Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin NCT01030432 | Bristol-Myers Squibb | Phase 2 |
| Completed | TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation an NCT01022125 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435 NCT01046058 | Tibotec Pharmaceuticals, Ireland | Phase 1 |
| Completed | Drug Interaction Oral Contraceptive Pill (OCP) NCT01063023 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV NCT01040039 | Rockefeller University | — |
| Completed | Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients NCT01006031 | Sociedad Andaluza de Enfermedades Infecciosas | Phase 2 / Phase 3 |
| Completed | Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED) NCT00896233 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection NCT01091077 | Massachusetts General Hospital | Phase 1 |
| Completed | Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population NCT00894257 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets NCT00861458 | Pfizer | Phase 1 |
| Completed | Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-048 NCT00810758 | Pfizer | Phase 1 |
| Completed | Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors NCT00819026 | University of Wisconsin, Madison | — |
| Terminated | Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocyto NCT00678587 | GlaxoSmithKline | Phase 3 |
| Completed | Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV NCT00705224 | Merck Sharp & Dohme LLC | — |
| Completed | Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Sub NCT00671671 | Pfizer | Phase 1 |
| Completed | Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficienc NCT00503347 | Peregrine Pharmaceuticals | Phase 1 |
| Completed | Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin NCT00382798 | Pharmasset | Phase 1 / Phase 2 |
| Completed | Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. NCT01195181 | Azienda Ospedaliera di Padova | Phase 4 |
| Completed | Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers NCT00342641 | National Cancer Institute (NCI) | — |
| Completed | Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation NCT00710801 | University of Alberta | — |
| Unknown | PEG-IFN Plus Ribavirin Combination Therapy for Older Patients NCT00956982 | Kyushu University | N/A |
| Completed | Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus NCT00143000 | NORDynamIC Study Group | Phase 4 |
| Terminated | Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribav NCT00194857 | Weill Medical College of Cornell University | Phase 4 |
| Completed | Hepatitis C Virus and the Humoral Immune System NCT00219999 | Rockefeller University | — |
| Completed | Study of Long-term Peg Intron vs. Colchicine in Non-responders. NCT00179413 | Beth Israel Deaconess Medical Center | Phase 4 |
| Withdrawn | Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C NCT00633230 | University of Virginia | Phase 1 |